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Following the publication of our article [1] we noticed an
error within Additional file 2: Comparison of patient
baseline characteristics by condition. The column head-
ings 'Control' and 'Intervention' are incorrectly positioned
in the table and should be switched.
The table should therefore appear as shown in Table 1 in
this correction.
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Table 1: Comparison of patient baseline characteristics by condition
Condition Group Characteristic Control n (%) Intervention n (%) Total n (%)
Diabetes N = 785 N = 1182 N = 1967
Male 432 (55.0) 651 (55.1) 1083 (55.1)
Age (years) Median (IQ range) 67.0 (59.0–74.0) 66.0 (58.0–73.0) 66.0 (59.0–73.0)
Aboriginal and Torres Strait Islander Yes 4 (0.5) 23 (1.9) 27 (1.4)
No 723 (92.1) 1036 (87.6) 1759 (89.4)
Missing 58 (7.4) 123 (10.4) 181 (9.2)
BMI Underweight 5 (0.6) 3 (0.3) 8 (0.4)
Normal 121 (15.4) 181 (15.3) 302 (15.4)
Overweight 243 (31.0) 386 (32.7) 629 (32.0)
Obese 334 (42.5) 464 (39.3) 798 (40.6)
Missing 82 (10.4) 148 (12.5) 230 (11.7)Trials 2009, 10:7 http://www.trialsjournal.com/content/10/1/7
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HbA1c % Median (IQ range) 7.1 (6.3–8.0) 6.9 (6.2–7.7) 7.0 (6.3–7.8)
Missing 64 (8.2) 90 (7.6) 154 (7.8)
Diabetes management:
Dietary control Yes 446 (56.8) 604 (51.1) 1050 (53.4)
No 309 (39.4) 503 (42.6) 812 (41.3)
Missing 30 (3.8) 75 (6.3) 105 (5.3)
Insulin Yes 145 (18.5) 204 (17.3) 349 (17.7)
No 610 (77.7) 903 (76.4) 1513 (76.9)
Missing 30 (3.8) 75 (6.3) 105 (5.3)
Prescription tablets Yes 541 (68.9) 729 (61.7) 1270 (64.6)
No 214 (27.3) 378 (32.0) 592 (30.1)
Missing 30 (3.8) 75 (6.3) 105 (5.3)
Years since first diagnosed < 1 year 39 (5.0) 67 (5.7) 106 (5.4)
1–5 years 256 (32.6) 403 (34.1) 659 (33.5)
6–10 years 201 (25.6) 235 (19.9) 436 (22.2)
> 10 years 230 (29.3) 311 (26.3) 541 (27.5)
Missing 59 (7.5) 166 (14.0) 225 (11.4)
Hyperlipidaemia N = 1463 N = 2356 N = 3819
Male 753 (51.5) 1277 (54.2) 2030 (53.2)
Age (years) Median (IQ range) 68.0 (60.0–74.0) 66.0 (58.0–74.0) 66.0 (59.0–74.0)
Aboriginal and Torres Strait Islander Yes 9 (0.6) 26 (1.1) 35 (0.9)
No 1342 (91.7) 2102 (89.2) 3444 (90.2)
Missing 112 (7.7) 228 (9.7) 340 (8.9)
Index of Relative Socio-Economic 
Disadvantage
1st quartile 251 (17.2) 575 (24.4) 826 (21.6)
2nd quartile 476 (32.5) 756 (32.1) 1232 (32.3)
3rd quartile 390 (26.7) 663 (28.1) 1053 (27.6)
4th quartile 346 (23.7) 362 (15.4) 708 (18.5)
Co-morbid conditions:
Known heart disease Yes 540 (36.9) 812 (34.5) 1352 (35.4)
No 869 (59.4) 1398 (59.3) 2267 (59.4)
Missing 54 (3.7) 146 (6.2) 200 (5.2)
Diabetes 509 (34.8) 853 (36.2) 1362 (35.7)
Smoking status Current 103 (7.0) 201 (8.5) 304 (8.0)
Ex-smoker 644 (44.0) 1001 (42.5) 1645 (43.1)
Never smoked 654 (44.7) 990 (42.0) 1644 (43.0)
Missing 62 (4.2) 164 (7.0) 226 (5.9)
Total cholesterol Median (IQ range) 4.7 (4.0–5.4) 4.6 (4.0–5.4) 4.7 (4.0–5.4)
Missing 99 (6.8) 186 (7.9) 285 (7.5)
Triglyceride Median (IQ range) 1.6 (1.1–2.2) 1.6 (1.2–2.2) 1.6 (1.2–2.2)
Missing 185 (12.6) 204 (8.7) 389 (10.2)
HDL-C Median (IQ range) 1.3 (1.1–1.6) 1.3 (1.1–1.5) 1.3 (1.1–1.6)
Missing 239 (16.3) 515 (21.9) 754 (19.7)
Anticoagulant therapy N = 372 N = 572 N = 944
Male 217 (58.3) 326 (57.0) 543 (57.5)
Age (years) Median (IQ range) 73.0 (66.0–79.0) 73.0 (65.0–78.0) 73.0 (65.0–79.0)
BMI Underweight 7 (1.9) 5 (0.9) 12 (1.3)
Normal 90 (24.2) 165 (28.8) 255 (27.0)
Overweight 130 (34.9) 190 (33.2) 320 (33.9)
Obese 111 (29.8) 132 (23.1) 243 (25.7)
Missing 34 (9.1) 80 (14.0) 114 (12.1)
Multiple co-morbidities Yes 170 (45.7) 285 (49.8) 455 (48.2)
No 186 (50.0) 259 (45.3) 445 (47.1)
Missing 16 (4.3) 28 (4.9) 44 (4.7)
INR Below target range 73 (19.6) 115 (20.1) 188 (19.9)
Within target range 197 (53.0) 316 (55.2) 513 (54.3)
Above target range 37 (9.9) 63 (11.0) 100 (10.6)
Missing 65 (17.5) 78 (13.6) 143 (15.1)
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